ArticleLung Cancer (Auckland, N.Z.)2017

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.

Wolfgang Schuette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.